Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 16/20 | 0.61 |
| ▸ | IGF1R | P08069 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | INSR | P06213 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15070957 | 0.89 | TNK2 (0.59) | TNK2IGF1REGFRINSRKDR | |
| SCHEMBL594237 | 0.85 | TNK2 (0.63) | TNK2IGF1RCYP3A4 | |
| SCHEMBL595274 | 0.83 | RAF1 (0.67) | TNK2IGF1REGFRINSRKDR | |
| SCHEMBL595275 | 0.83 | RAF1 (0.67) | TNK2IGF1REGFRINSRKDR | |
| SCHEMBL15070961 | 0.81 | TNK2 (0.63) | TNK2IGF1RRAF1SRCCYP3A4 | |
| SCHEMBL15070958 | 0.80 | TNK2 (0.51) | TNK2IGF1REGFRINSRKDR | |
| SCHEMBL1129026 | 0.76 | TNK2 (1.00) | TNK2 | |
| SCHEMBL1129024 | 0.76 | TNK2 (1.00) | TNK2 | |
| SCHEMBL594585 | 0.74 | IGF1R (0.77) | TNK2IGF1REGFRINSRKDR | |
| SCHEMBL594587 | 0.74 | IGF1R (0.77) | TNK2IGF1REGFRINSRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | TNK2 669/4885IGF1R 1033/4885EGFR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.